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Profiling the mutational landscape of coagulation
factor V deficiency
Coagulation factor V (FV) is a 330 kDa procofactor of
the coagulation cascade that, upon activation, con-
tributes to the formation of the prothrombinase complex,
essential for the rapid generation of thrombin.1 FV defi-
ciency (Online Mendelian Inheritance in Man #227400;
https://www.omim.org/) is an autosomal recessive disorder,
with an estimated prevalence in the general population
of 1:1 million.2 The most common forms of FV deficiency
are characterized by FV antigen (FV:Ag) levels that can
vary from mildly reduced to unmeasurable (quantitative
defect), whereas qualitative defects, showing
normal/moderately decreased antigen levels associated
with reduced FV coagulant activity (FV:C), are far rarer.2
Clinical manifestations range from mild bleeding (such as
epistaxis, hematomas, easy bruising, and menorrhagia) to
severe gastrointestinal or central nervous system hemor-
rhages.2 Both monoallelic and biallelic mutations in the
FV gene (F5; 25 exons, 75 kb of length, chromosome
1q24.2) have been associated with FV quantitative
defects, for a total of 139 mutations (Human Gene
Mutation Database, public version, http://
www.hgmd.cf.ac.uk/ac/index.php; accessed on April 05,
2019). Here, we present phenotype/genotype data on the
largest cohort of FV deficient patients analyzed so far. In
addition, integrating our results with the huge amount of
data coming from F5-specific and genomic databases, we
defined the mutational landscape of FV deficiency and
estimated its world-wide prevalence.
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Figure 1. Demographic and
clinical characteristics of
the case series. Local Ethics
Committees approved this
study. All individuals (or
their parents, if minor)
signed an informed consent
according to the Declaration
of Helsinki. Data on the
enrolled 50 coagulation fac-
tor V (FV)-deficient patients
are presented as aggregat-
ed. Pie-charts and his-
tograms illustrate the coun-
try of origin (A), the female
to male ratio (B), the classi-
fication of patients accord-
ing to the severity of the
deficiency (C), and the distri-
bution of age at diagnosis
(D). Data on sex and age are
missing for one patient. FV
coagulant (FV:C) and FV
antigen (FV:Ag) levels are
detailed in panel (E), where
the number of each patient
is reported on the X axis,
and corresponds to the
numbering (P1-P50) report-
ed in Table 1. FV:C and
FV:Ag were measured as
described;3 normal ranges
for both tests are 60-140%.
All patients were measured
for FV:C, except P36 (for
whom only FV:Ag is report-
ed). Patients lacking FV:Ag
measurements are indicat-
ed by an asterisk. Patients
showing a discordance
>30% between FV:C and
FV:Ag are marked by a dot.
In panel (F), the list of all
major bleeding episodes,
affecting nine patients (evi-
denced with a rectangle in
panel E), is reported.
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Table 1. Genetic data of the coagulation factor V-deficient patients.
Severity  Patient    Type of mutation         cDNA level*                      Native protein                  Mature protein**           Status              In silico
                                                                                                                                                                                                                 analysis***
Severe FV deficiency
                      P1                 missense                  c.1321C>T                              p.Arg441Cys                           p.Arg413Cys                         comp hetero      PD, B, B
                                           nonsense                  c.5630C>A                    p.Ser1877X                  p.Ser1849X                                                    n.d.
                      P2                 nonsense                  c.3481C>T                              p.Arg1161X                             p.Arg1133X                           comp hetero      n.d.
                                       small deletion              c.3924_3927delTCAG           p.Ser1308ArgfsX24               p.Ser1280ArgfsX24                                           n.d.
                      P3                 missense                  c.5189A>G                              p.Tyr1730Cys                         p.Tyr1702Cys                        homo                   D, D, D
                      P4                 missense                  c.5189A>G                              p.Tyr1730Cys                         p.Tyr1702Cys                        homo                   D, D, D
                      P5                 nonsense                  c.2404C>T                    p.Gln802X                    p.Gln774X                         homo                   n.d.
                      P6                 nonsense                  c.3088C>T                              p.Arg1030X                             p.Arg1002X                           homo                   n.d.
                      P7            small insertion             c.3153_3154insCT       p.Arg1052LeufsX44     p.Arg1024LeufsX44   homo                   n.d.
                      P8                 nonsense                  c.3481C>T                              p.Arg1161X                             p.Arg1133X                           homo                   n.d.
                      P9            small deletion              c.3296delA                              p.Asp1099AlafsX72               p.Asp1071AlafsX72             homo                   n.d.
                     P10                missense                  c.6305G>A                              p.Arg2102His                         p.Arg2074His                       comp hetero      D, D, D
                                            missense                  c.6197G>A                    p.Cys2066Tyr               p.Cys2038Tyr                                                D, D, D
                     P11                missense                  c.5765A>C                    p.Gln1922Pro               p.Gln1894Pro                  homo                   D, D, D
                     P12                missense                  c.5215G>T                    p.Asp1739Tyr               p.Asp1711Tyr                  homo                   D, D, D
                     P13                missense                  c.6182G>A                    p.Cys2061Tyr               p.Cys2033Tyr                  comp hetero      D, D, D
                                           nonsense                  c.2218C>T                              p.Arg740X                               p.Arg712X                                                           n.d.
                     P14                missense                  c.6293C>G                    p.Pro2098Arg               p.Pro2070Arg                  homo                   D, D; D
                     P15                nonsense                  c.5807T>A                    p.Leu1936X                  p.Leu1908X                      comp hetero      n.d.
                                            missense                  c.6304C>T                              p.Arg2102Cys                         p.Arg2074Cys                                                     D, D, D
                     P16           small deletion              c.1600delC                    p.Arg534LysfsX40       p.Arg506LysfsX40        comp hetero      n.d.
                                       small deletion              c.4933delG                   p.Gly1645ValfsX19      p.Gly1617ValfsX19                                    n.d.
                     P17                missense                  c.1340C>G                    p.Pro447Arg                 p.Pro419Arg                    comp hetero      PD, D, D
                                      small insertion             c.5052_5053insTTTC   p.Thr1685PhefsX4       p.Thr1657PhefsX4                                     n.d.
                     P18                missense                  c.692T>G                                p.Met231Arg                          p.Met203Arg                        homo                   PD, D, D
                     P19                missense                  c.6492G>C                    p.Trp2164Cys               p.Trp2136Cys                  homo                   PD, D, D
                     P20           small deletion              c.2862delT                              p.Ser955AlafsX4                    p.Ser927AlafsX4                  homo                   n.d.
                     P21                missense                  c.320A>G                      p.Asp107Gly                 Asp79Gly                           homo                   PD, D, B
                     P22                nonsense                  c.2841G>A                    p.Trp947X                     p.Trp919X                         homo                   n.d.
                     P23                missense                  c.1883G>A                    p.Gly628Glu                 p.Gly600Glu                     homo                   PD, D, D
                     P24                missense                  c.6649G>A                    p.Glu2217Lys               p.Glu2189Lys                  homo                   D, D, D
                     P25                missense                  c.1883G>A                    p.Gly628Glu                 p.Gly600Glu                     homo                   PD, D, D
                     P26                missense                  c.5005T>C                    p.Ser1669Pro               p.Ser1641Pro                  homo                   D, D, PD
                     P27           small deletion              c.2862delT                              p.Ser955AlafsX4                    p.Ser927AlafsX4                  homo                   n.d.
                     P28           small deletion              c.2862delT                              p.Ser955AlafsX4                    p.Ser927AlafsX4                  homo                   n.d.
                     P29           small deletion              c.2862delT                              p.Ser955AlafsX4                    p.Ser927AlafsX4                  homo                   n.d.
Mild FV deficiency
                     P30                missense                  c.6304C>T                              p.Arg2102Cys                         p.Arg2074Cys                       hetero                 D, D, D
                     P31                missense                  c.6443T>C                              p.Met2148Thr                        p.Met2120Thr                      hetero                 B, D, D
                                       polymorphism              
                     P32           HR2 haplotype              p.Met385Thr, p.His1299Arg, p.Met1736Val, p.Asp2194Gly                                  hetero                 PD, D, D
                     P33           HR2 haplotype              p.Met385Thr, p.His1299Arg, p.Met1736Val, p.Asp2194Gly                                  hetero                 PD, D, D
                     P34           HR2 haplotype              p.Met385Thr, p.His1299Arg, p.Met1736Val, p.Asp2194Gly                                  hetero                 PD, D, D
                     P35                missense                  c.134G>A                      p.Gly15Asp                   p.Gly-14Asp                     hetero                 PD, B, B
                     P36                nonsense                  c.5474G>A                    p.Trp1825X                   p.Trp1797X                       hetero                 n.d.
                     P37                missense                  c.1652T>C                    p.Phe551Ser                p.Phe523Ser                    hetero                 PD, D, D
                     P38                missense                  c.5993G>T                    p.Ser1998Ile                p.Ser1970Ile                   hetero                 D, D, D
continuing on next page
We enrolled 50 patients (P1-P50) with partial/severe FV
deficiency, whose main demographic/clinical characteris-
tics are summarized in Figure 1. A total of 29 patients suf-
fered from severe FV deficiency (FV:C, <13%); 21 had
partial deficiency: among them, six patients were charac-
terized by levels of FV:C close to the lower limit of the
normal range (FV:C normal range=60-140%).3 Only nine
patients referred major bleeding, the most recurrent type
being intracranial hemorrhage (Figure 1). Of note, three
patients suffering from severe bleeding had FV levels
(FV:C=12%, 13%, and 35%) that should be able to sus-
tain a quasi-normal hemostasis (recommended FV levels
in case of surgery or severe bleeding are ~20-25%).4
Hence, our data confirm yet again the lack of correlation
between the clinical expression of the deficiency and
plasma FV level.5
Screening for mutations was performed by Sanger
sequencing of the F5 coding regions and splice junctions.
We disclosed a total of 42 different variants, five of which
(p.Gly600Glu, p.Ser927AlafsX4, p.Arg1133X,
p.Tyr1702Cys, p.Arg2074Cys) were found in more than
one patient, and 29 were novel (17 missense, six non-
sense, six indels) (Table 1; Online Supplementary Figure
S1A). We checked for the newly identified variants in the
GnomAD repository (reporting data on >125,000 exomes
and >15,000 genomes from European, African, Asian,
and Admixed American populations;
https://gnomad.broadinstitute.org/; accessed on April 05,
2019) and only found p.Cys2033Tyr, p.Pro419Arg, and
p.Ser1641Pro at an extremely low frequency (1-3 alleles
in >250,000), and the more common p.Arg313Cys vari-
ant at a frequency of 7.6*10-4.
During the genetic screening we also found: i) three
patients heterozygous for the p.Met2120Thr variant, a
functional polymorphism determining a ~25% reduction
in FV levels;6 ii) six patients heterozygous for the HR2
haplotype (Table 1). This haplotype is composed of a
group of >10 linked genetic polymorphisms and is
known to confer a partial FV deficiency.2,7 The functional
dissection of the four missense variants constituting the
haplotype (i.e. p.Met385Thr, p.His1299Arg,
p.Met1736Val, p.Asp2194Gly) demonstrated a major
contribution to the quantitative defect of the
p.Asp2194Gly substitution (~70% reduction in FV lev-
els), whereas moderately decreased secretion rates were
detected for the p.Met385Thr and p.His1299Arg FV pro-
teins.8
All missense variants, including the p.Met2120Thr and
p.Asp2194Gly polymorphisms, as well as previously
reported mutations (Online Supplementary Table S1),
involve highly-conserved residues. They were all in silico
analyzed by using three prediction programs
(MutationAssessor, SIFT, PolyPhen2) through the Variant
Effect Predictor tool (https://www.ensembl.org/
info/docs/tools/vep/index.html). This analysis consistently
predicted as deleterious a subset of 12 missense variants,
whereas the remaining substitutions (including some
already reported as a cause of FV deficiency) were predict-
ed with conflicting results (Table 1). With these premises,
to give conclusive results on the possible pathogenic role
of the newly identified missense substitutions, we studied
their impact on FV synthesis/secretion ex vivo. Site-direct-
ed mutagenesis was used to introduce in the pcDNA3-FV
vector each missense substitution. We mirrored the wild-
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                     P39           small deletion              c.1134_1135delCA       p.His379PhefsX3         p.His351PhefsX3          comp hetero      n.d.
                                       HR2 haplotype              p.Met385Thr, p.His1299Arg, p.Met1736Val, p.Asp2194Gly                                                                PD, D, D
                     P40           small deletion              c.5093delA                    p.Asn1698MetfsX37    p.Asn1670MetfsX37    hetero                 n.d.
                     P41                nonsense                  c.4650C>G                    p.Tyr1550X                   p.Tyr1522X                       comp hetero      n.d.
                                       HR2 haplotype              p.Met385Thr, p.His1299Arg, p.Met1736Val, p.Asp2194Gly                                                                 PD, D, D
                     P42                nonsense                  c.2862delT                              p.Ser955AlafsX4                    p.Ser927AlafsX4                  hetero                 n.d.
                     P43                nonsense                  c.3481C>T                              p.Arg1161X                             p.Arg1133X                           hetero                 n.d.
                     P44                missense                  c.6419G>A                              p.Gly2140Asp                         p.Gly2112Asp                       hetero                 D, D, D
                     P45                missense                  c.4906G>A                              p.Glu1636Lys                         p.Glu1608Lys                       hetero                 PD, B, D
                     P46                missense                  c.5683G>C                    p.Gly1895Arg               p.Gly1867Arg                  hetero                 D, D, D
                     P47                missense                  c.1021C>T                    p.Arg341Cys                 p.Arg313Cys                    comp hetero      PD, B, D
                                           missense                  c.6443T>C                              p.Met2148Thr                        p.Met2120Thr                                                    B, D, D
                                       polymorphism              
                     P48                missense                  c.1309A>G                    p.Asn437Asp                p.Asn409Asp                   comp hetero      PD, D, B
                                           missense                  c.6443T>C                              p.Met2148Thr                        p.Met2120Thr                                                    B, D, D
                                       polymorphism              
                     P49           HR2 haplotype              p.Met385Thr, p.His1299Arg, p.Met1736Val, p.Asp2194Gly                                hetero                 PD, D, D
                     P50           small deletion              c.2862delT                              p.Ser955AlafsX4                    p.Ser927AlafsX4                  hetero                 n.d.
All mutations, including those previously reported in the literature, were named following the official recommendations of the Human Genome Variation Society (HGVS,
http://www.hgvs.org/mutnomen/recs-DNA.html). For mutation names at the protein level, the three-letter code annotation was adopted. Newly-described mutations are
bolded. In the case of the HR2 allele, the four major missense variants contributing to the haplotype are listed. Previously reported mutations are listed also in the Online
Supplementary Table S1, where the relevant reference is cited. *Numbering starting from ATG, according to NM_000130.4. **Numbering omitting the signal peptide (28
amino-acid long). ***Pathogenicity predictions for missense mutations were performed using three programs (MutationAssessor, SIFT, PolyPhen2), available through the
Variant Effect Predictor online (https://www.ensembl.org/info/docs/tools/vep/index.html). As for the HR2 haplotype, only the p.Asp2194Gly was analysed. A missense vari-
ant was classified as deleterious if consistently predicted as such by 3 of 3 programs. Results of prediction are reported as D: deleterious mutation; PD: probably deleterious
mutation. B: benign. FV: coagulation factor V; n.d.: not done; homo: homozygous; hetero: heterozygous; comp hetero: compound heterozygous. 
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type/mutant homozygous conditions in COS-1 cells (not
expressing FV) by transiently transfecting either the wild-
type or each of the mutant constructs. We hence harvest-
ed recombinant [35S]-pulse-labelled FV molecules by
immunoprecipitation both from cell lysates and condi-
tioned media and performed SDS-PAGE analysis.9
With regards to intracellular FV, we observed a band
corresponding to the wild-type or mutant protein in all
cases (Figure 2A). As for conditioned media, we detected
a severe reduction in the quantity of all mutant mole-
cules, suggesting a secretion impairment (i.e. the “typi-
cal” consequence at the protein level of F5 missense
mutations);2 the only exception regarded the p.Asp79Gly
mutant, which was detected as a band almost compara-
ble to the one observed for the wild-type condition
(Figure 2B). These results were confirmed both by FV:Ag
evaluation in cell lysates and serum-free conditioned
media by ELISA, and by FV:C assays performed on cul-
ture media (Figure 2C-E). Specifically concerning the
p.Asp79Gly substitution, only a slight reduction in anti-
gen/functional levels were observed (~30/38% reduc-
tion), making the effects of this variant comparable to
those of the p.Met2120Thr polymorphism.
Altogether, our results indicate that all of the 29 newly
identified substitutions (including 17 missense) can be
regarded as truly pathogenic, thus increasing the number
of mutations causing FV deficiency by 21%. The distri-
bution of these defects according to their position along
the F5 gene is reported in the Online Supplementary Figure
S1B. Here, the almost complete lack of missense variants
in the unstructured B domain is evident. Interestingly,
the most upstream homozygous truncating mutation is
located at position 77310 strengthening the concept that
in humans a complete FV deficiency is incompatible
with life.2
To have a comprehensive picture of the burden of
potentially deleterious mutations in the F5 gene, we also
collected data from the GnomAD database. Among the
reported variants, we retrieved all null mutations (non-
sense, indels, and splice mutations involving the first or
last two intronic nucleotides) plus non-synonymous
variants annotated as damaging by 3 of 3 prediction pro-
grams. We found 178 variants in ~250,000 different alle-
les, all present in the heterozygous state. We excluded
from this calculation the common p.Met2120Thr variant
and the four missense polymorphisms of the HR2 haplo-
type. The F5 mutational landscape in the general popu-
lation mirrors the mutational spectrum observed for the
deficiency, both in terms of mutation scattering along
the gene, and of the distribution of mutation types
(Online Supplementary Figure S1C-E). Hence, we used the
GnomAD data to infer the world-wide prevalence of
severe FV deficiency (i.e. due to homozygous or com-
pound heterozygous mutations), using an approach sim-
ilar to that already adopted for other rare inherited coag-
ulation defects.11,12 We estimated a world-wide preva-
lence rate of 1 in 2 million for severe FV deficiency in the
general population, even rarer than that reported in the
literature so far.5 Certainly we have to recognize some
limitations relative to our prevalence estimate, also con-
sidering that FV is a double-faced molecule with both
pro-thrombotic and anti-thrombotic characteristics.2,7
Some among the rare mutations included in the calcula-
tion could indeed be associated with the production of a
dysfunctional molecule with a pro-thrombotic behavior
(as in the case of the relatively common Leiden muta-
tion, p.Arg506Gln),13 thus overestimating the prevalence
rate of the deficiency. On the other hand, we used strin-
gent conditions in predicting the pathogenicity of muta-
tions (as demonstrated above; Table 1), thus possibly
underestimating the prevalence rate. In addition, it is
well-known that exome data lack information not only
on deep-intronic/promoter mutations and gross dele-
tion/rearrangements by design, but also on indel muta-
tions for problems intrinsic to variant-caller programs,
thus again possibly leading us to underestimate the FV-
deficiency prevalence. In any case, the Leiden mutation
was not included in our prevalence calculation; impor-
tantly, this genetic defect is not properly reported in
GnomAD, where p.Gln506 (p.Gln534Arg according to
official nomenclature) is erroneously considered the ref-
erence allele and the Gln-to-Arg substitution is flagged
as “dubious”.
As for common FV-lowering functional defects, i.e.
p.Met2120Thr and the HR2-tagging variant
p.Asp2194Gly, in GnomAD they show an allele frequen-
cy of 3.1% and 6.3%, respectively, testifying that a mild
deficiency for FV could be rather common in the general
population. In the Online Supplementary Figure S2we also
report the frequencies of the HR2 haplotype in different
populations, estimated by using either in-house or pub-
licly available data. This analysis shows that HR2 is
absent among Africans, is relatively rare in East Asians
(2.7%) and it is quite common in other populations,
reaching the notable frequency of 8.2% among Admixed
Americans. This observation could be of particular
importance, especially considering that the HR2 allele
can be present in trans with the Leiden mutation, exac-
erbating its pro-thrombotic effect, as in the case of the
pseudo-homozygous activated protein C resistance.14
In conclusion, this work reports the largest case series
of FV-deficient patients described so far, increases the
number of FV-causing mutation by one fifth, and paints
-for the first time- the complete world-wide mutational
landscape for the F5 gene. 
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